GSK plc (NYSE:GSK) Shares Acquired by Roberts Wealth Advisors LLC

Roberts Wealth Advisors LLC increased its position in shares of GSK plc (NYSE:GSK) by 2.1% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 85,376 shares of the pharmaceutical company’s stock after purchasing an additional 1,760 shares during the quarter. Roberts Wealth Advisors LLC’s holdings in GSK were worth $3,246,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Jamison Private Wealth Management Inc. raised its holdings in GSK by 4.6% during the third quarter. Jamison Private Wealth Management Inc. now owns 17,849 shares of the pharmaceutical company’s stock worth $730,000 after purchasing an additional 784 shares during the last quarter. Foster Victor Wealth Advisors LLC raised its holdings in GSK by 5.0% during the third quarter. Foster Victor Wealth Advisors LLC now owns 272,917 shares of the pharmaceutical company’s stock worth $10,982,000 after purchasing an additional 13,045 shares during the last quarter. Creative Planning raised its holdings in GSK by 3.9% during the third quarter. Creative Planning now owns 211,100 shares of the pharmaceutical company’s stock worth $8,630,000 after purchasing an additional 7,854 shares during the last quarter. Sivia Capital Partners LLC acquired a new position in GSK during the third quarter worth $209,000. Finally, Thomasville National Bank raised its holdings in GSK by 2.5% during the third quarter. Thomasville National Bank now owns 475,384 shares of the pharmaceutical company’s stock worth $19,434,000 after purchasing an additional 11,771 shares during the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, major shareholder Plc Gsk bought 2,791,930 shares of the stock in a transaction dated Friday, September 27th. The stock was bought at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the acquisition, the insider now owns 16,775,691 shares of the company’s stock, valued at $134,205,528. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 10.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Argus raised GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Berenberg Bank raised GSK to a “strong-buy” rating in a research report on Thursday, June 20th. UBS Group downgraded GSK from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Jefferies Financial Group boosted their price target on GSK from $52.50 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, July 2nd. Finally, Barclays raised GSK to a “hold” rating in a research report on Tuesday, August 27th. Four research analysts have rated the stock with a hold rating, two have issued a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $50.00.

GSK Trading Down 0.4 %

NYSE:GSK opened at $38.96 on Wednesday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.54 and a current ratio of 0.82. GSK plc has a one year low of $33.67 and a one year high of $45.92. The business’s 50-day simple moving average is $41.50 and its 200 day simple moving average is $41.32. The stock has a market cap of $80.74 billion, a price-to-earnings ratio of 14.12, a price-to-earnings-growth ratio of 1.30 and a beta of 0.65.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.09. GSK had a return on equity of 51.48% and a net margin of 12.87%. The firm had revenue of $9.95 billion for the quarter, compared to analysts’ expectations of $9.49 billion. As a group, sell-side analysts predict that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, October 10th. Stockholders of record on Friday, August 16th were issued a dividend of $0.3843 per share. The ex-dividend date was Friday, August 16th. This is a positive change from GSK’s previous quarterly dividend of $0.38. This represents a $1.54 annualized dividend and a dividend yield of 3.95%. GSK’s dividend payout ratio is 55.80%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.